All In Biotech

Drug Trial Radar · NCT02528123

VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia

Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

114

Actual

Start

Apr 2016

Primary completion

Dec 7, 2020

Study completion Dec 7, 2020

Sponsor

Lead sponsor
London Vision ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to validate the safety and effectiveness of treating myopia (short-sightedness) higher than -10D using small incision lenticule extraction (SMILE) with the VisuMax femtosecond laser.

Conditions

  • Myopia
  • Refractive Errors

Interventions

  • Small incision lenticule extractionProcedure

    The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.

  • Tobramycin and dexamethasoneDrug

    Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure

  • OfloxacinDrug

    Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure

  • Proxymetacaine 0.5%Drug

    Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure

  • Oxybuprocaine 0.4%Drug

    Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Variability of the Refractive PredicatibilityTime frame: 1 year postop

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • London Vision Clinic

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.